N. Khushalani

N. Khushalani, C. Lao, T. Petrella, 2022, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis

A. Hauschild, D. Schadendorf, I. Lowy, 2021, Journal for ImmunoTherapy of Cancer.

Melanocortin 1 Receptor–Targeted α-Particle Therapy for Metastatic Uveal Melanoma

E. Moros, M. Budzevich, D. Boulware, 2019, The Journal of Nuclear Medicine.

The “Great Debate” at Melanoma Bridge 2021, December 2nd–4th, 2021

P. Ascierto, S. Demaria, H. Tawbi, 2022, Journal of translational medicine.

Long-term follow up of lifileucel (LN-144) cryopreserved autologous tumor infiltrating lymphocyte therapy in patients with advanced melanoma progressed on multiple prior therapies.

J. Larkin, J. Kirkwood, H. Kluger, 2020 .

Acute motor axonal neuropathy after ipilimumab and nivolumab treatment in melanoma brain metastases: A case report and review of the literature

N. Tran, H. Tawbi, K. Margolin, 2021, SAGE open medical case reports.

Single cell characterization of the cellular landscape of acral melanoma identifies novel targets for immunotherapy.

V. Sondak, F. Karreth, K. Smalley, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.

P. Ascierto, J. Larkin, A. Arance, 2020, The Lancet. Oncology.

BRAF and beyond: Tailoring strategies for the individual melanoma patient

N. Khushalani, A. Jarkowski, 2014, Journal of carcinogenesis.

Efficacy and safety of nivolumab (NIVO) plus ipilimumab (IPI) in patients with melanoma (MEL) metastatic to the brain: Results of the phase II study CheckMate 204.

M. Atkins, F. Hodi, H. Tawbi, 2017 .

Efficacy and safety of the combination of nivolumab (NIVO) plus ipilimumab (IPI) in patients with symptomatic melanoma brain metastases (CheckMate 204).

M. Atkins, F. Hodi, H. Tawbi, 2019, Journal of Clinical Oncology.

Safety and efficacy of combination nivolumab plus ipilimumab in patients with advanced melanoma: results from a North American expanded access program (CheckMate 218)

M. Atkins, F. Hodi, M. Smylie, 2020, Melanoma research.

Neoadjuvant chemotherapy for primary cutaneous/soft tissue angiosarcoma: Determining tumor behavior prior to surgical resection

J. Kane, K. Attwood, N. Khushalani, 2015, Journal of surgical oncology.

Current and future approaches in the surgical management of T3b/T4 primary and locoregionally advanced melanoma

V. Sondak, J. Messina, R. Neves, 2022, Cancer.

Adjuvant nivolumab versus ipilimumab (CheckMate 238 trial): Reassessment of 4-year efficacy outcomes in patients with stage III melanoma per AJCC-8 staging criteria.

P. Ascierto, A. Arance, P. Queirolo, 2022, European journal of cancer.

Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.

R. Sullivan, J. Sosman, Douglas B. Johnson, 2016, JAMA oncology.

Analysis of clinical and dosimetric factors associated with change in renal function in patients with gastrointestinal malignancies after chemoradiation to the abdomen.

G. Wilding, M. Fakih, K. May, 2010, International Journal of Radiation Oncology, Biology, Physics.

LBA3_PRA PHASE 3 RANDOMIZED, OPEN-LABEL STUDY OF NIVOLUMAB (ANTI-PD-1; BMS-936558; ONO-4538) VERSUS INVESTIGATOR'S CHOICE CHEMOTHERAPY (ICC) IN PATIENTS WITH ADVANCED MELANOMA AFTER PRIOR ANTI-CTLA-4 THERAPY

G. Linette, F. Hodi, S. D'Angelo, 2014 .

Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204)

M. Atkins, F. Hodi, H. Tawbi, 2021, Neuro-oncology.

789 Lifileucel TIL cell monotherapy in patients with advanced melanoma after progression on immune checkpoint inhibitors (ICI) and targeted therapy: pooled analysis of consecutive cohorts (C-144–01 study)

J. Kirkwood, P. Hari, H. Kluger, 2022, Regular and Young Investigator Award Abstracts.

Bempegaldesleukin plus nivolumab in untreated, unresectable or metastatic melanoma: Phase III PIVOT IO 001 study design.

P. Ascierto, J. Larkin, M. Sznol, 2020, Future oncology.

Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma

T. Kirchhoff, G. Gibney, D. Woods, 2022, Journal for immunotherapy of cancer.

Patterns of histologic response to neoadjuvant targeted therapy in patients with BRAF mutant melanoma.

V. Sondak, J. Messina, J. Markowitz, 2017 .

Respiratory syncytial virus infection in the late bone marrow transplant period: report of three cases and review

M. Czuczman, N. Khushalani, A. Mohr, 2001, Bone Marrow Transplantation.

PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma

A. Hauschild, D. Schadendorf, C. Chung, 2018, The New England journal of medicine.

Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial.

C. Berking, A. Hauschild, D. Schadendorf, 2020, The Lancet. Oncology.

Melanoma, version 2.2013: featured updates to the NCCN guidelines.

A. Halpern, S. Swetter, M. Ross, 2013, Journal of the National Comprehensive Cancer Network : JNCCN.

Whole-genome sequencing of a malignant granular cell tumor with metabolic response to pazopanib

C. Morrison, Q. Hu, Jianmin Wang, 2015, Cold Spring Harbor molecular case studies.

Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer.

Judy L. Smith, H. Nava, W. Greco, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Regional Radiation Therapy Impacts Outcome for Node-Positive Cutaneous Melanoma.

V. Sondak, T. Strom, S. Eschrich, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma

J. Larkin, J. Kirkwood, H. Kluger, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Erlotinib and Radiation Therapy for Elderly Patients with Esophageal Cancer - Clinical and Correlative Results from a Prospective Multicenter Phase 2 Trial

C. LeVea, R. Iyer, N. Khushalani, 2013, Oncology.

Occult primary.

D. Ettinger, A. Rashid, L. Kvols, 2008, Journal of the National Comprehensive Cancer Network : JNCCN.

Evaluation of phosphatidylinositol-3-kinase catalytic subunit (PIK3CA) and epidermal growth factor receptor (EGFR) gene mutations in pancreaticobiliary adenocarcinoma.

J. Cowell, J. Gibbs, M. Rossi, 2013, Journal of gastrointestinal oncology.

A phase II trial of erlotinib monotherapy in advanced pancreatic cancer as a first- or second-line agent

A. Hutson, G. Warren, W. Ma, 2017, Cancer Chemotherapy and Pharmacology.

The High-Dose Aldesleukin “Select” Trial: A Trial to Prospectively Validate Predictive Models of Response to Treatment in Patients with Metastatic Renal Cell Carcinoma

R. Figlin, A. Belldegrun, Su-Chun Cheng, 2014, Clinical Cancer Research.

Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.

A. Hauschild, D. Schadendorf, J. Taube, 2022, The New England journal of medicine.

Pralatrexate in Combination with Oxaliplatin in Advanced Esophagogastric Cancer: A Phase II Trial with Predictive Molecular Correlates

A. Adjei, S. Patnaik, M. Opyrchal, 2019, Molecular Cancer Therapeutics.

Intralesional and systemic immunotherapy for metastatic melanoma

J. Zager, N. Khushalani, C. Luu, 2016, Expert opinion on biological therapy.

Dose rounding of ipilimumab in adult metastatic melanoma patients results in significant cost savings*

N. Khushalani, A. Jarkowski, Karen L Vona, 2014, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.

Principles of Targeted Therapy for Melanoma.

James X. Sun, N. Khushalani, Michael J. Carr, 2020, The Surgical clinics of North America.

NCCN Melanoma Clinical Practice Guidelines in Oncology

A. Halpern, S. Swetter, M. Ross, 2012 .

Systemic Therapy in Advanced Cutaneous Squamous Cell Carcinoma (CSCC): The Roswell Park Experience and a Review of the Literature

K. May, J. Kane, J. Skitzki, 2016, American journal of clinical oncology.

Cancer of the esophagus and stomach.

N. Khushalani, 2008, Mayo Clinic proceedings.

Aorto-esophageal fistula: a rare fatal case caused by esophageal malignancy.

H. Nava, S. Yendamuri, N. Khushalani, 2010, Journal of gastrointestinal oncology.

Systemic Therapy for Melanoma: ASCO Guideline.

V. Sondak, P. Ascierto, M. Atkins, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Immunotherapy in Melanoma

N. Khushalani, A. Jarkowski, Megan M. Saraceni, 2015, Journal of pharmacy practice.

Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)

J. Serody, A. Ivanova, E. Dees, 2021, Melanoma research.

Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing

A. Hauschild, D. Schadendorf, I. Lowy, 2020, Journal for immunotherapy of cancer.

NCI 8628: A randomized phase 2 study of ziv‐aflibercept and high‐dose interleukin 2 or high‐dose interleukin 2 alone for inoperable stage III or IV melanoma

J. Kirkwood, A. Chen, H. Tawbi, 2018, Cancer.

Primary analysis of phase 2 results of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with locally advanced cutaneous squamous cell carcinoma (laCSCC).

C. Berking, A. Hauschild, D. Schadendorf, 2019, Journal of Clinical Oncology.

Phase 2 study of cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with metastatic cutaneous squamous cell carcinoma (mCSCC; Group 1): 12-month follow-up.

A. Hauschild, I. Lowy, R. Gutzmer, 2019, Journal of Clinical Oncology.

1094TiP A randomized, controlled, open-label, phase II study of cemiplimab as a single agent and in combination with RP1 in patients with advanced cutaneous squamous cell carcinoma [CERPASS]

G. Daniels, D. Rischin, A. Haydon, 2021, Annals of Oncology.

MelanomaPractice Guidelines in Oncology

A. Halpern, S. Swetter, M. Ross, 2012 .

Phase II study of cemiplimab in patients (pts) with advanced cutaneous squamous cell carcinoma (CSCC): Longer follow-up.

A. Hauschild, D. Schadendorf, I. Lowy, 2020 .

Significant antitumor activity for low-dose ipilimumab (IPI) with pembrolizumab (PEMBRO) immediately following progression on PD1 Ab in melanoma (MEL) in a phase II trial.

V. Sondak, T. Karrison, D. Olson, 2020 .

Phase II trial of pembrolizumab (pembro) plus 1 mg/kg ipilimumab (ipi) immediately following progression on anti-PD-1 Ab in melanoma (mel).

V. Sondak, T. Karrison, D. Olson, 2018 .

Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator's Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial.

D. Schadendorf, G. Linette, C. Horak, 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma.

S. Ibrahim, S. Chandra, M. Migden, 2020, Future oncology.

Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.

D. Ayers, N. Khushalani, S. Keeping, 2021, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

Phase 2 Study of Cemiplimab in Patients with Advanced Cutaneous Squamous Cell Carcinoma (CSCC): Longer Follow-Up

A. Hauschild, D. Schadendorf, I. Lowy, 2020 .

Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study

Michael E. Egger, J. Kirkwood, P. Hari, 2022, Journal for ImmunoTherapy of Cancer.

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.

J. Kirkwood, H. Kluger, K. Lewis, 2021, Journal of Clinical Oncology.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

J. Utikal, D. Schadendorf, V. Sondak, 2017, European journal of cancer.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, Brian D. Kelly, 2016, Journal of Immunotherapy for Cancer.

Combined BRAF and HSP90 Inhibition in Patients with Unresectable BRAFV600E-Mutant Melanoma

V. Sondak, G. Gibney, K. Smalley, 2018, Clinical Cancer Research.

Melanoma, Version 2.2013 Featured Updates to the NCCN Guidelines

A. Halpern, S. Swetter, M. Ross, 2013 .

Surveillance of Sentinel Node-Positive Melanoma Patients Who Receive Adjuvant Therapy Without Undergoing Completion Lymph Node Dissection

James X. Sun, V. Sondak, M. Schabath, 2021, Annals of Surgical Oncology.

Interferon is associated with improved survival for node-positive cutaneous melanoma: a single-institution experience

V. Sondak, T. Strom, J. Torres-Roca, 2018, Melanoma management.

A Rare Case of Missing Primary in Metastatic Renal Cell Carcinoma

N. Khushalani, S. Gandhi, Ankita Kapoor, 2020, Cureus.

Combined nivolumab and ipilimumab with or without stereotactic body radiation therapy for advanced Merkel cell carcinoma: a randomised, open label, phase 2 trial

V. Sondak, C. Chung, R. Slebos, 2022, The Lancet.

Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.

L. Harrison, P. Johnstone, A. Naghavi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Matrix Metalloproteinases in Gastric Cancer

N. Khushalani, N. Ramnath, 2006 .

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

V. Sondak, T. Karrison, D. Olson, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors with targeted therapies

P. Ascierto, M. Atkins, J. Sosman, 2023, Journal for ImmunoTherapy of Cancer.

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

P. Ascierto, M. Del Vecchio, M. Mandalà, 2021, Journal for ImmunoTherapy of Cancer.

Outcomes with adjuvant anti-PD-1 therapy in patients with sentinel lymph node-positive melanoma without completion lymph node dissection

James X. Sun, Lesly A. Dossett, T. Hieken, 2022, Journal for ImmunoTherapy of Cancer.

Safety and efficacy of cryopreserved autologous tumor infiltrating lymphocyte therapy (LN-144, lifileucel) in advanced metastatic melanoma patients who progressed on multiple prior therapies including anti-PD-1.

J. Larkin, J. Kirkwood, H. Kluger, 2019, Journal of Clinical Oncology.

Management of intussusception in patients with melanoma

James X. Sun, V. Sondak, R. Gonzalez, 2019, Journal of surgical oncology.

Ipilimumab/nivolumab‐induced pseudolymphoma in a patient with malignant melanoma

J. Messina, N. Khushalani, L. Seminario-Vidal, 2020, Journal of cutaneous pathology.

High-dose interleukin-2 therapy for metastatic renal cell carcinoma: a contemporary experience.

K. Attwood, R. Pili, N. Khushalani, 2014, Urology.

Secondary gliosarcoma with extra-cranial metastases: A report and review of the literature

A. Fabiano, Jingxin Qiu, N. Khushalani, 2013, Clinical Neurology and Neurosurgery.

Malignant adnexal tumors of the skin: a single institution experience

J. Kane, J. Skitzki, N. Khushalani, 2018, World Journal of Surgical Oncology.

Detection of a possible case of pulmonary tumour thromboembolism by endobronchial ultrasound.

S. Dhillon, N. Khushalani, I. Berim, 2012, Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace.

Outcomes of endoscopic resection for high-grade dysplasia and esophageal cancer

H. Nava, G. Wilding, S. Hochwald, 2014, Surgical Endoscopy.

A phase I pharmacokinetic (PK) study of vorinostat (V) in combination with irinotecan (I), 5-fluorouracil (5FU), and leucovorin (FOLFIRI) in advanced upper gastrointestinal cancers (AGC).

C. LeVea, R. Iyer, N. Khushalani, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I and II clinical trials for gastric cancer.

N. Khushalani, 2012, Surgical oncology clinics of North America.

A phase II study of first-line biweekly capecitabine and bevacizumab in elderly patients with metastatic colorectal cancer.

G. Wilding, M. Fakih, N. Khushalani, 2009, Critical reviews in oncology/hematology.

Effect of Concurrent Radiation Therapy and Chemotherapy on Pulmonary Function in Patients with Esophageal Cancer: Dose‐Volume Histogram Analysis

Judy L. Smith, H. Nava, L. Blumenson, 2002, Cancer journal.

Effectiveness of Adjuvant Pembrolizumab vs High-Dose Interferon or Ipilimumab for Quality-of-Life Outcomes in Patients With Resected Melanoma: A Secondary Analysis of the SWOG S1404 Randomized Clinical Trial.

V. Sondak, J. Kirkwood, A. Ribas, 2022, JAMA oncology.

1473 Mechanism of action of bempegaldesleukin (BEMPEG) plus nivolumab (NIVO) in patients with unresectable or metastatic melanoma from the phase 3 randomized open-label PIVOT IO-001 clinical trial

M. Zhou, H. Gogas, C. Lebbé, 2022, Late-Breaking Abstracts.

Case report of pneumatosis intestinalis secondary to sunitinib treatment for refractory gastrointestinal stromal tumor.

N. Khushalani, A. Jarkowski, N. Wilkinson, 2011, Anticancer research.

Efficacy, Safety, and Potential Biomarkers of Sunitinib and Transarterial Chemoembolization (TACE) Combination in Advanced Hepatocellular Carcinoma (HCC): Phase II Trial

E. Ashton, S. Ait-Oudhia, R. Iyer, 2016, American journal of clinical oncology.

Adjuvant pembrolizumab versus interferon alfa-2b or ipilimumab in resected high-risk melanoma.

V. Sondak, M. Knopp, J. Kirkwood, 2021, Cancer discovery.

Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response to treatment with IL2 and antiangiogenic therapies.

Su-Chun Cheng, S. Signoretti, B. Leibovich, 2013 .

Neoadjuvant BRAF‐targeted therapy in regionally advanced and oligometastatic melanoma

V. Sondak, J. Messina, J. Markowitz, 2020, Pigment cell & melanoma research.

CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).

P. Ascierto, J. Larkin, M. Sznol, 2019, Journal of Clinical Oncology.

Cetuximab for Immunotherapy-Refractory/Ineligible Cutaneous Squamous Cell Carcinoma

J. Markowitz, A. Brohl, N. Khushalani, 2023, Cancers.

Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study

Jihnhee Yu, R. Iyer, N. Khushalani, 2008, Anti-cancer drugs.

Phase I Study of Irinotecan/5-Fluorouracil/Leucovorin (FOLFIRI) with Sunitinib for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

K. Attwood, R. Iyer, N. Khushalani, 2019, Targeted Oncology.

Abstract CT013: S1616: Ipilimumab plus nivolumab versus ipilimumab alone in patients with metastatic or unresectable melanoma that did not respond to anti-PD-1 therapy

J. Sosman, A. Ribas, J. Moon, 2022, Cancer Research.

Clinical T2N0M0 carcinoma of thoracic esophagus.

N. Khushalani, Gary Y. Yang, T. Wagner, 2010, Journal of thoracic disease.

Circulating tumor DNA‐based molecular residual disease detection for treatment monitoring in advanced melanoma patients

J. Messina, J. Markowitz, M. Malhotra, 2023, Cancer.

S-phase modulation by irinotecan: pilot studies in advanced solid tumors

Y. Rustum, L. Pendyala, H. Slocum, 2005, Cancer Chemotherapy and Pharmacology.

Duration of Anti-Programmed Death-1 Therapy in Advanced Melanoma: How Much of a Good Thing Is Enough?

N. Khushalani, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I trial of panobinostat with ipilimumab in advanced melanoma.

M. Schell, J. Markowitz, J. Weber, 2017 .

A phase II, randomized study of nivolumab (NIVO) and Ipilimumab (IPI) versus NIVO, IPI and stereotactic body radiation therapy (SBRT) for metastatic Merkel cell carcinoma (MCC, NCT03071406): A preliminary report

J. Messina, L. Harrison, J. Russell, 2019, Annals of Oncology.

Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by IL-6 blockade

K. Tsai, N. Ajami, G. Calin, 2023, Research square.

PIVOT-12: a Phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.

D. Schadendorf, P. Ascierto, G. Boland, 2022, Future oncology.

Ipilimumab with or without nivolumab in PD-1 or PD-L1 blockade refractory metastatic melanoma: a randomized phase 2 trial

J. Sosman, A. Ribas, P. Scumpia, 2023, Nature Medicine.

Stereotactic Radiosurgery and Anti-PD-1 + CTLA-4 Therapy, Anti-PD-1 Therapy, Anti-CTLA-4 Therapy, BRAF/MEK Inhibitors, BRAF Inhibitors, or Conventional Chemotherapy for the Management of Melanoma Brain Metastases

N. Tran, M. Vogelbaum, Youngchul Kim, 2023, European Journal of Cancer.

Echoes of a failure: what lessons can we learn?

V. Sondak, N. Khushalani, 2019, The Lancet Oncology.

Systemic Therapy for Melanoma: ASCO Guideline Update

V. Sondak, P. Ascierto, M. Atkins, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238

P. Ascierto, A. Arance, P. Queirolo, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Adjuvant and Neoadjuvant Therapy in High-Risk Stage III Cutaneous Melanoma.

V. Sondak, N. Khushalani, 2017, International Journal of Radiation Oncology, Biology, Physics.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): late breaking abstracts

Amanda R. Campbell, F. Lund-Johansen, Yair Benita, 2016 .

Combined BRAF, MEK, and heat‐shock protein 90 inhibition in advanced BRAF V600‐mutant melanoma

V. Sondak, K. Smalley, A. Brohl, 2023, Cancer.

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

G. Linette, C. Horak, P. Ascierto, 2015, The Lancet. Oncology.

Clinical outcomes of melanoma brain metastases treated with stereotactic radiosurgery and anti-PD-1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy.

L. Harrison, P. Johnstone, A. Naghavi, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Cancer of unknown primary presenting with liver metastasis: a cost, time to treatment and outcome analysis.

M. Ahluwalia, R. Iyer, N. Khushalani, 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).

Cancer of the esophagus and stomach.

N. Khushalani, 2008, Mayo Clinic proceedings.

31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part one

Charles J. Vaske, Rohan N. Borkar, David M. Schauder, 2016, Journal for ImmunoTherapy of Cancer.

Bempegaldesleukin Plus Nivolumab in Untreated Advanced Melanoma: The Open-Label, Phase III PIVOT IO 001 Trial Results

P. Ascierto, M. Sznol, H. Gogas, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Neoadjuvant cemiplimab and surgery for stage II-IV cutaneous squamous-cell carcinoma: follow-up and survival outcomes of a single-arm, multicentre, phase 2 study.

J. Homsi, N. Khushalani, P. Swiecicki, 2023, The Lancet. Oncology.

Regional chemotherapy is indicated after surgical resection of colorectal metastases to the liver: A debate

N. Petrelli, J. Gibbs, C. Leichman, 2003, Journal of surgical oncology.

6603 A phase II study of erlotinib in patients (pts) with advanced pancreatic cancer (APC) who are refractory to gemcitabine (G)

A. Hutson, A. Adjei, M. Fakih, 2009 .

Multicenter phase II study of gemcitabine, capecitabine, and bevacizumab in patients with advanced pancreatic cancer (APC): Final analysis of clinical and quality of life endpoints

C. Garrett, Jihnhee Yu, R. Iyer, 2008 .

Scheduled administration of low dose irinotecan before gemcitabine in the second line therapy of non-small cell lung cancer: a phase II study

Y. Rustum, Jihnhee Yu, R. Iyer, 2008, Anti-cancer drugs.

Breaking the barriers in cancer care: The next generation of herpes simplex virus-based oncolytic immunotherapies for cancer treatment

A. Melcher, N. Khushalani, P. Bommareddy, 2023, Molecular therapy oncolytics.

Final results of urelumab, an anti-CD137 agonist monoclonal antibody, in combination with cetuximab or nivolumab in patients with advanced solid tumors

N. Segal, J. Neely, S. Suryawanshi, 2024, Journal for ImmunoTherapy of Cancer.

Ipilimumab in metastatic melanoma patients with pre-existing autoimmune disorders.

J. Sosman, Douglas B. Johnson, I. Puzanov, 2015 .